Article Information
History
- February 26, 2021.
Article Versions
- Version 1 (February 22, 2021 - 08:48).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Michele Atzl, MD1,
- Axel Muendlein, PhD2,
- Thomas Winder, MD1,
- Peter Fraunberger, MD3,4,
- Eva-Maria Brandtner, PhD2,
- Kathrin Geiger, PhD2,3,
- Miriam Klausberger, PhD5,
- Mark Duerkop, PhD5,
- Lukas Sprenger, MD1,2,
- Beatrix Mutschlechner, MD1,4,
- Andreas Volgger, MD1,
- Magdalena Benda, MD1,
- Luciano Severgnini, MD1,
- Johannes B. Jaeger, MD1,
- Heinz Drexel, MD2,4,6,7,
- Alois Lang, MD8 and
- Andreas Leiherer, PhD2,3,4,*
- 1Department of Internal Medicine II, Academic Teaching Hospital Feldkirch, Feldkirch, Austria
- 2Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria
- 3Medical Central Laboratories, Feldkirch, Austria
- 4Private University of the Principality of Liechtenstein, Triesen, Liechtenstein
- 5Department of Biotechnology, University of Natural Resources and Life Sciences (BOKU) Vienna, Vienna, Austria
- 6Department of Internal Medicine, Academic Teaching Hospital Bregenz, Bregenz, Austria
- 7Drexel University College of Medicine, Philadelphia, PA, USA
- 8Cancer Registry Vorarlberg, Agency for Preventive and Social Medicine, Bregenz Austria
- ↵*Address for correspondence
Andreas Leiherer, Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Academic Teaching Hospital Feldkirch, Feldkirch, Austria, Carinagasse 47, A-6800 Feldkirch, Austria; E-mail address: vivit{at}lkhf.at